You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
|
|---|---|
| Published in |
Frontiers in oncology, December 2014
|
| DOI | 10.3389/fonc.2014.00349 |
| Pubmed ID | |
| Authors |
Kim De Veirman, Els Van Valckenborgh, Qods Lahmar, Xenia Geeraerts, Elke De Bruyne, Eline Menu, Ivan Van Riet, Karin Vanderkerken, Jo A. Van Ginderachter |
| Abstract |
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature myeloid cells that accumulate during pathological conditions such as cancer and are associated with a poor clinical outcome. MDSC expansion hampers the host anti-tumor immune response by inhibition of T cell proliferation, cytokine secretion, and recruitment of regulatory T cells. In addition, MDSC exert non-immunological functions including the promotion of angiogenesis, tumor invasion, and metastasis. Recent years, MDSC are considered as a potential target in solid tumors and hematological malignancies to enhance the effects of currently used immune modulating agents. This review focuses on the characteristics, distribution, functions, cell-cell interactions, and targeting of MDSC in hematological malignancies including multiple myeloma, lymphoma, and leukemia. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 143 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 2 | 1% |
| France | 1 | <1% |
| Poland | 1 | <1% |
| Unknown | 139 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 36 | 25% |
| Student > Ph. D. Student | 26 | 18% |
| Student > Master | 16 | 11% |
| Other | 15 | 10% |
| Student > Bachelor | 12 | 8% |
| Other | 22 | 15% |
| Unknown | 16 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 28% |
| Agricultural and Biological Sciences | 28 | 20% |
| Biochemistry, Genetics and Molecular Biology | 22 | 15% |
| Immunology and Microbiology | 17 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
| Other | 9 | 6% |
| Unknown | 24 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2021.
All research outputs
#2,721,340
of 25,373,627 outputs
Outputs from Frontiers in oncology
#673
of 22,416 outputs
Outputs of similar age
#36,673
of 368,088 outputs
Outputs of similar age from Frontiers in oncology
#3
of 94 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,416 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 368,088 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.